Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research
Berwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Cheng Fang, Ph.D., as its new Vice President of Research."I am excited to welcome Dr. Fang to Annovis Bio. Her knowledge of research in our field, as well as in general, is excellent," commented Maria Maccecchini, Ph.D., CEO of...
2021-05-18 8:30 AM EDT
Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - May 13, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive orphan drug designation for its lead drug candidate, ANVS401, for the treatment of AD in persons with Down syndrome (DS), referred to as DS-AD.DS occurs in...
2021-05-13 8:30 AM EDT
Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that management will participate at the Benzinga Global Small Cap Conference taking place online May 13-14, 2021.Annovis Bio CEO Maria Maccecchini, Ph.D. will deliver a corporate presentation at 3:10 p.m. ET on May 13, 2021. Investors can request...
2021-05-11 6:45 AM EDT
Annovis Bio to Ring Closing Bell at the New York Stock Exchange
Berwyn, Pennsylvania--(Newsfile Corp. - May 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, is pleased to announce that its CEO Maria Maccecchini, Ph.D. will ring The Closing Bell at the New York Stock Exchange (NYSE) today, May 10, to celebrate the recent reporting of positive interim data from its ongoing Phase 2a trial in AD and PD."We are honored...
2021-05-10 2:00 PM EDT
Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic Encephalopathy
Berwyn, Pennsylvania--(Newsfile Corp. - May 6, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the U.S. Patent and Trademark Office (USPTO) granted the Company's patent (US 16/504,813) for a method of treating tauopathies, such as frontotemporal dementia and chronic traumatic encephalopathy by administering ANVS401. This is the Company's...
2021-05-06 6:45 AM EDT
Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
Berwyn, Pennsylvania--(Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company's lead compound, ANVS401, to normalize brain development in Down Syndrome (DS)...
2021-04-29 7:00 AM EDT
Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
Berwyn, Pennsylvania--(Newsfile Corp. - April 15, 2021) - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Reid S. McCarthy to its Board of Directors and to the role of Audit Committee chairman, effective April 9, 2021.A specialist in bank, bond, and equity financings, McCarthy retired after serving from 2016 to 2019 as CFO of JJ Haines &...
2021-04-15 7:30 AM EDT
Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
Berwyn, Pennsylvania--(Newsfile Corp. - March 17, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Dr. Maria L. Maccecchini is presenting at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC. The online conference takes place March 17 and 18 from 9:00 a.m. to 5:00 p.m. EST.To learn how to attend,...
2021-03-17 6:45 AM EDT
Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
Berwyn, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results of an interim analysis from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of PD and AD. Patients' speed and coordination scores both improved following 25 days of ANVS401 treatment, with...
2021-03-16 6:45 AM EDT
Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
Berwyn, Pennsylvania--(Newsfile Corp. - March 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it signed an agreement for up to 10 kg of GMP-manufactured ANVS401 to support the Company's planned late-stage studies in Alzheimer's in Down syndrome (AD-DS), PD and AD. "The existing supply of our lead candidate, ANVS401, has been allocated...
2021-03-11 7:00 AM EST
Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
Berwyn, Pennsylvania--(Newsfile Corp. - March 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the Japan Patent Office (JPO) granted the Company's patent (2018-527851) for the treatment or prevention of acute brain or nerve injury by administering ANVS405."This new patent further strengthens our intellectual property focused on the...
2021-03-10 7:00 AM EST
Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
Berwyn, Pennsylvania--(Newsfile Corp. - March 9, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. Annovis Bio's presentation will be available online beginning March 9, 2021 at 7:00 a.m. ET., and the...
2021-03-09 7:30 AM EST
Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
Berwyn, Pennsylvania--(Newsfile Corp. - February 4, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) granted the Company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury."This new patent, covering acute indications, joins our two patents covering our...
2021-02-04 6:45 AM EST
Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
Berwyn, Pennsylvania--(Newsfile Corp. - February 2, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin-α (PFT-α) after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other...
2021-02-02 6:45 AM EST
Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 11-14, 2021.The on-demand presentation will be available beginning January 11 at 6:00 a.m. EST and can be accessed through the...
2021-01-05 6:45 AM EST